Koshimichi H, Ishibashi T, Wajima T. Population Pharmacokinetics of Baloxavir Marboxil in Japanese Pediatric Influenza Patients. J Pharm Sci. 2019 Apr 15.
Baloxavir marboxil is a prodrug of baloxavir acid, an inhibitor of cap-dependent endonuclease, and suppresses the replication of influenza virus. The aim of this study is to investigate its pharmacokinetic characteristics in Japanese pediatrics. Population pharmacokinetic analysis was conducted for baloxavir acid with 328 plasma concentration data points in a clinical study of 107 Japanese pediatric influenza patients. The plasma baloxavir acid concentration profiles were well captured by a two-compartment model including first-order absorption and lag time. Body weight was considered to be the most crucial covariate which affects clearance and volume of distribution. The body weight-based dose regimen (10 mg for 10 kg to less than 20 kg pediatrics, 20 mg for 20 kg to less than 40 kg pediatrics, and 40 mg for at least 40 kg pediatrics) for Japanese pediatrics can provide comparable exposure to baloxavir acid to that for adults. In conclusion, the population pharmacokinetic model would be useful to comprehend the characteristics of baloxavir acid pharmacokinetics in pediatric patients.
See Also:
Latest articles in those days:
- Phylogeography and gene pool analysis of highly pathogenic avian influenza H5N1 viruses reported in India from 2006 to 2021 14 hours ago
- Analysis of a diffusive epidemic model with a zero-infection zone 15 hours ago
- Quick detection of H5N1 avian influenza virus by surface enhanced Raman scattering(SERS) using aptamer capture 15 hours ago
- The critical role of RAGE in severe influenza infection: A target for control of inflammatory response in the disease 15 hours ago
- Human infection caused by avian influenza A (H10N5) virus 15 hours ago
[Go Top] [Close Window]